This Small Business Innovative Research (SBIR) Phase I project will address the production, characterization and application of antibodies to carbonaceous nanomaterials. Specifically, these are the trimetallic endohedral fullerene, Trimetaspheres (TMS). The project will develop the novel nanomaterials and produce immunoprobes and affinity matrices based on monoclonal and polyclonal anti-TMS antibodies. These will be used to evaluate the effects of the TMS as contrasting and therapeutic agents.
The immunological tools developed will play an important role in the development and use of the TMS as contrasting and therapeutic agents. The use of these tools will expand the scientific and technological understanding of the chemistry, cell-mediated responses and the pharmacokinetics of these innovative TMS reagents.
